A retrospective analysis of risk factors for severity of nosocomial COVID-19 in patients with hematological malignancy


Posted: 2021-11-04 19:00:00
Background: With the global spread of coronavirus disease 2019 (COVID-19), patients with cancer may be at a higher risk of suffering from COVID-19. Although patients with hematological malignancy (HM) are reported to have a higher risk of severe COVID-19 compared with those with solid cancer, the effects of treatment for HM on COVID-19 severity have not been fully elucidated. Methods: We retrospectively analyzed the risk factors, including number and timing of chemotherapeutic regimens for HM, for COVID-19 severity in 17 patients with HM, who had developed nosocomial COVID-19 in our department, by dividing them into two groups; a severe group (N=7) and a non-severe group (N=10). Results: The overall mortality rate was 47%, and mortality in the severe group was significantly higher than that in the non-severe group (odds ratio [OR], 18.44; 95% confidence interval [CI], 1.27-1223.17, P=0.02). Univariate analysis identified two or more chemotherapeutic regimens for HM (OR, 17.34; 95%CI, 1.15-1165.33, P=0.03) and a low hemoglobin level (P=0.02) as significant risk factors for COVID-19 severity. However, a history of chemotherapy for HM within 3 months prior to the onset of COVID-19 was not a significant risk factor (P=0.54). Conclusion: A history of multiple chemotherapeutic regimens in patients with HM may be a risk factor for COVID-19 severity, and physicians should be aware of this. Keywords: COVID-19; Hematological malignancy; Multiple chemotherapeutic regimens; Nosocomial infection.

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
6月 01, 2020 バイオアソシエイツ

英国政府、犬によるCOVID-19の一斉迅速検出を推進

2020年5月15日、英国政府は迅速な COVID-19 の非侵襲的検査が行える特別に訓練されたバイオ検出犬を見つけ出するために、500,000ポンド(約6500万円)以上を研究チームに授与したことを発表した。臨床試験の第1フェーズでは、ロンドン医療衛生熱帯大学(LSHTM:London School of Hygiene & Tropical Medicine)の世界をリードする疾患管理の専門家がMedical Detection Dogsおよび…

ゲスト 588人 と メンバー 2人 がオンラインです